NextCure, Inc.
NXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661059
In the last 90 days, NextCure, Inc. insiders filed 2 open-market purchases and 1 sale; 30 institutions reported holding it in 13F filings for Q2 2026, worth $2.78M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding NextCure, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 43 | 41 | −2 |
| Shares | 13.3M | 12.9M | −423.3K (−3.2%) |
| Value | $24.0M | $16.6M | −$7.34M (−30.6%) |
New holders (3)
Institutions that held NextCure, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State of Wyoming | 2,613 | $3.37K | 0.00% |
| Qube Research & Technologies Ltd | 48 | $62 | 0.00% |
| Bank of America Corp | 2 | $2 | 0.00% |
Sold out (5)
Institutions that held NextCure, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Cardiff Park Advisors, LLC | 262,000 | $471.6K |
| Assenagon Asset Management S.A. | 43,917 | $79.1K |
| Cutler Group LP | 700 | $1.00K |
| Northwestern Mutual Wealth Management Co | 550 | $990 |
| Royal Bank of Canada | 46 | $0 |